Compare Tenet Healthcare Corporation (THC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tenet Healthcare Corporation vs Tango Therapeutics Inc. — how do they compare? Tenet Healthcare Corporation trades at $271.76 (market cap $21.87B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tenet Healthcare Corporation is far larger — about 5.8× Tango Therapeutics Inc.'s market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tenet Healthcare Corporation for 16 Days and Tango Therapeutics Inc. for 0 Days on average.
| THC | TNGX | |
|---|---|---|
Market Cap | $21.87B | $3.74B |
Volume | 717,275 | 3,438,781 |
Sector | Health | Health |
52-Week High | $280.77 | $32.90 |
52-Week Low | $161.37 | $7.50 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $32.95B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tenet Healthcare (THC) trades at $266.91, down 0.69% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with three consecutive quarterly earnings beats and impressive profitability metrics including 82.83% gross margins and 53.31% ROE. Recent news highlights continued investor interest and upcoming Q3 2026 earnings release on October 29.
THC presents a compelling investment case with attractive valuation (P/E 10.32), strong analyst support (81% buy rating), and 6.2% upside to consensus target of $283.36. Key risks include cash flow sustainability for capital return strategy and potential surgical volume pressures. The stock's combination of value pricing and growth execution supports continued upside potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
